Fusion Antibodies Share Discussion Threads

[gwr7] 18/9/2020 12:52

Jumping the gun a little but couldn't resist.

GWR7 17 Apr '20 - 10:00 - 46 of 49
When I suggested you hold on for the ride I meant more than ten minutes. The CEO gave more information than provided in the RNS. Let's reconvene in 6 months and see who was right. Price currently 116p.

[tidy 2] 18/9/2020 12:48

700p ps should come with easy cap wise it will be 150m

[phil1969] 18/9/2020 12:46

Nice bit of consolidation at £2. When I bough in earlier this morning I thought I'd hold this for a couple of weeks but now I've spent more time digging, looks like this is set to run for the rest of 2020 if the updates keep coming.

[tidy 2] 18/9/2020 12:29

This news is related to FAB with Roche hTTps://www.globenewswire.com/news-release/2020/09/18/2095622/0/en/Roche-launches-new-quantitative-antibody-test-to-measure-SARS-CoV-2-antibodies-to-support-the-evaluation-of-vaccines.htmlhTTps://www.globenewswire.com/news-release/2020/09/18/2095622/0/en/Roche-launches-new-quantitative-antibody-test-to-measure-SARS-CoV-2-antibodies-to-support-the-evaluation-of-vaccines.htmlBasel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.1 Specifically, the test targets antibodies which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell. The majority of current candidate vaccines aim to induce an antibody response against the spike protein."As the possibility of an effective SARS-CoV-2 vaccine becomes a reality, quantitative measurement of antibodies will be crucial in the evaluation of any potential vaccine. The new quantitative Elecsys antibody test can play a pivotal role in vaccine clinical trials as well as helping clinicians assess patients immune response.This will be instrumental in protecting people most vulnerable to the virus, as well as in overcoming COVID-19 for society in general." said Thomas Schinecker, CEO Roche Diagnostics. "This new test, the twelfth in the Roche SARS-CoV-2 testing portfolio, is another essential addition to support healthcare systems and patients as we jointly fight COVID-19."

[tomboyb] 18/9/2020 12:25

Its looking v interesting -

Not new to FAB as i initially bought at around the 80p levels but sold out -

However in today early so looking forward to see what transpires -

[tidy 2] 18/9/2020 12:19

Market radars totally blindsided by this news and company for that matter. Tiny free float tiny cap. Base 700p ps imo.

[superg1] 18/9/2020 12:18

Tidy

I did spot that but didn't research it, too busy and now on other bits today.

But in theory big pharma will sign up and I see no reason, based on others why this shouldn't hit £150mill to £200mill MC in short order.

It will take a while for investors to realise the basics of the business and that no big raises are needed at all.

On the face of it the antigens alone look like they beat what others are doing.

[phil1969] 18/9/2020 12:14

Holding 10k for the next week or two. Will be very interesting.

[tidy 2] 18/9/2020 12:09

SuperG1 what do you make of this. hTTps://www.globenewswire.com/news-release/2020/09/18/2095622/0/en/Roche-launches-new-quantitative-antibody-test-to-measure-SARS-CoV-2-antibodies-to-support-the-evaluation-of-vaccines.htmlRoche made this announcement this morning - based on the timing and the similarity in the descriptions of what they do I wonder if the two announcements are related

[tomboyb] 18/9/2020 12:09

v illiquid -

[hodhasharon] 18/9/2020 12:07

Time to move to GDR?

[tidy 2] 18/9/2020 12:05

Yes at 700p ps its scratching the base. Imo

[superg1] 18/9/2020 12:04

I'm just dropping in the details rapidly so that serious PIs can catch up.

I had been busy just starting to tell friends about it over the last week then that news dropped in at 9.30.

[superg1] 18/9/2020 12:03

I say cursing but £7 is the £150 mill marker.

Even then on a 15 PE it equates to just £12 mill profit.

So few shares in issues means a 15 PE equates to 57p on the share price per mill profit

[tidy 2] 18/9/2020 12:01

Potential turns to success. Leaders in antibody discovery, development and supply Active COVID-19 programme targeting end solution by summer that can be licensedParticipation in the NICADA consortium to find antibody to neutralise COVID-19Revenue generation underpins business with year on year growth Leading Humanisation technology succeed where others failAntibody Library that has potential to bring drugs and therapies to market fasterAcute Respiratory Disease Syndrome partnership with AqualungAntibodies really are the future

[superg1] 18/9/2020 12:01

Tidy

FAB is not yet on the map as such but will be in the coming week or so.

Most booing in now won;t have adman clue about FAB they will assume big cash needed which is completely wrong. That's what I love about FAB.

Very low risk, very big upside.

It's the fault of Pis not doing their own research that accuses cones like this to be missed.

Doc will be saying hey I saw it but he probably trading in and out, currently cursing now.

[tidy 2] 18/9/2020 11:57

Avct 472m cap. FAB 54m cap and look at the list of majors they supply.

[superg1] 18/9/2020 11:56

Tidy

I looked deeply, the underlying antibody business has been doing well, and they have new tech called RAMP (how apt)

So the actual basic business is growing well, low spend good income, something like 80% plus up re revenue.

With various virus false alarms over the years panic came and went, Covid has changed that and the innovative companies like Fusion were likely to see material interest in their tech and service.

If you listen to the CEO he states that customer have failed come to Fusion and got what they needed, hence the Fusion tech/'brand name' is good in the view of Pharmas.

Hence the CEO thought on the back of Covid. Now is the perfect time to showcase our tech.

Now is the time for the antibody tech to shine through.

[roger148] 18/9/2020 11:54

Im buying more on every dip Ridiculously low mcap and shares Mms will shake out stale holdersLike avct isnt producing any revenue but os over 300m mcap

[tidy 2] 18/9/2020 11:51

FAB Only £54m cap currently. The herd are still tucked away stirring at covid stocks that have already 30 bagged from this level and FAB provide 8 of the big pharmas the goods to work with.

[roger148] 18/9/2020 11:44

Going back up and nt to buy in volume

[tidy 2] 18/9/2020 11:44

FAB game changer. Engineering Covid killing antibodies for big pharma to take forward to neutralise Covid in patients.Great info SuperG1

[billthebank] 18/9/2020 11:44

Ahhh here we go tree shake!!! HOW BIG!!!?

[billthebank] 18/9/2020 11:39

Incredible day for pharmas.Missed out on FAB but bever know there may be big tree shake.After all nearly up 300% Dont often do this but look at GDR if you havent already. Also low c/v.

Would recommend researching!!

[superg1] 18/9/2020 11:37

Tidy

Those are all testing companies.

This is the testing option AND covid killing option.

To be honest in the early days I hadn't even considered they could offer testing answers, until they mentioned antigens in news. I was entirely focused on the main part of Covid killing meds.

Engineering Covid killing antibodies for big pharma to take forward to neutralise Covid in patients.